Cytokine-based NK stimulation has also been used in clinics or has reached the clinical trial phase, such as the application of Bempegaldesleukin (also named BEMPEG or NKTR-214, an IL-2 pathway agonist) for treating melanoma [98], and the short-term continuous infusion of IL-15 (NK expansion) for treating lymphoma [99]. Here, IL2 is linked to melanoma.